Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supernus Pharmaceuticals, Inc.

https://www.supernus.com/

Latest From Supernus Pharmaceuticals, Inc.

Keeping Track: US FDA Clears Another CAR-T And Another Novel ADHD Drug; Submissions Blossom

The latest news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Approvals Drug Review

Keeping Track: Regeneron Wins US FDA OK For Evkeeza, New Libtayo Uses; G1 Cosela Cleared

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Approvals

Keeping Track: Keytruda Adds TNBC Claim; Finerenone, Brincidofovir, HTX-011 Submitted; CRL For Supernus’ ADHD Drug

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Drug Review

12 Approvals To Look Out For In Q4

The end of the year should see a flurry of new products reaching the market to break new commercial ground or shake up their respective therapeutic areas. Here, Scrip takes a look at 12 of the more interesting approvals expected in the coming months, with the help of analysts at Biomedtracker.

Approvals Commercial
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Biscayne Neurotherapeutics, Inc.
    • Biscayne Neurotherapeutics Australia Pty, Ltd
    • Shire plc
    • Shire Laboratories Inc
UsernamePublicRestriction

Register